Archive - April 2019
FDA green light for Merck’s Mavenclad
Second chance for AstraZeneca’s selumetinib with breakthrough designation
Novartis strengthens anti-inflammatory drugs portfolio with IFM Tre buy
FDA label expansion for UCB’s Cimzia
No-deal Brexit could mean temporary medicines export ban
Novartis bolsters anti-inflammatory R&D with $1.6bn IFM Tre buy
Bluebird’s Zynteglo kicks off first Amsterdam CHMP recommendations
Top 5 Strongest Marijuana Strains In Terms Of THC Levels
